Quest Diagnostics Cash Flow from Investing Activities 2012-2026 | DGX
Quest Diagnostics annual/quarterly cash flow from investing activities history and growth rate from 2012 to 2026. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
- Quest Diagnostics cash flow from investing activities for the quarter ending March 31, 2026 was $-0.440B, a 78.49% decline year-over-year.
- Quest Diagnostics cash flow from investing activities for the twelve months ending March 31, 2026 was $-3.342B, a 10.47% decline year-over-year.
- Quest Diagnostics annual cash flow from investing activities for 2024 was $-2.548B, a 140.15% increase from 2023.
- Quest Diagnostics annual cash flow from investing activities for 2023 was $-1.061B, a 95.4% increase from 2022.
- Quest Diagnostics annual cash flow from investing activities for 2022 was $-0.543B, a 2685.71% decline from 2021.
|
Quest Diagnostics Annual Cash Flow Investing (Millions of US $) |
|
|---|---|
| 2024 | $-2,548 |
| 2023 | $-1,061 |
| 2022 | $-543 |
| 2021 | $21 |
| 2020 | $-772 |
| 2019 | $-411 |
| 2018 | $-801 |
| 2017 | $-830 |
| 2016 | $-127 |
| 2015 | $-362 |
| 2014 | $-1,025 |
| 2013 | $328 |
| 2012 | $-217 |
| 2011 | $-1,243 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $21.197B | $11.035B |
| Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fresenius SE (FSNUY) | Germany | $29.514B | 13.37 |
| Elanco Animal Health (ELAN) | United States | $11.500B | 24.35 |
| Encompass Health (EHC) | United States | $10.662B | 19.64 |
| DaVita (DVA) | United States | $10.023B | 13.82 |
| Chemed (CHE) | United States | $5.639B | 19.57 |
| Option Care Health (OPCH) | United States | $4.553B | 18.71 |
| RadNet (RDNT) | United States | $4.302B | 142.13 |
| LifeStance Health (LFST) | United States | $2.495B | 320.00 |
| Addus HomeCare (ADUS) | United States | $1.719B | 16.61 |
| Astrana Health (ASTH) | United States | $1.536B | 31.40 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.353B | 12.20 |
| U.S Physical Therapy (USPH) | United States | $1.157B | 29.19 |
| Pennant (PNTG) | United States | $1.072B | 31.31 |
| Daxor (DXR) | United States | $0.048B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.032B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |